Syndax Announces Presentation at 40th Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass. - Syndax Pharmaceuticals, Inc. ('Syndax,' the 'Company' or 'we') (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced that Briggs W. Morrison, M.D., Chief Executive Officer of Syndax, will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 08:15 a.m. ET.

A live webcast of the presentation can be accessed from the Investor section of the Company's website at www.syndax.com, where a replay of the event will also be available for a limited time.

About Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company's pipeline includes SNDX-5613, a highly selective inhibitor of the Menin-MLL binding interaction, axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, and entinostat, a class I HDAC inhibitor.

Contact:

Investor

Melissa Forst

Argot Partners

E: [e-mail]

Tel: [phone]

Media

Benjamin Kolinski

E: [e-mail]

Tel: [phone]

(C) 2022 Electronic News Publishing, source ENP Newswire